## Contents

Contributors, vii
Preface to the Second Edition, ix
Reviews of the First Edition, x
Acknowledgments and Dedication, xi
About the Companion Website, xii

**Introduction, 1**

1 Overview of Cancer Biology, 3
   *Michael Khan and Stella Pelengaris*
   - Introduction, 5
   - Cancer incidence and epidemiology, 8
   - Towards a definition of cancer, 8
   - Causes of cancer, 16
   - Cancer is a genetic disease, 21
   - Cancers (and Darwin’s finches) evolve by mutation and natural selection, 21
   - Blame the parents – inherited single gene defects and susceptibility to cancer, 21
   - The cancer “roadmap” – What kinds of genes are epimutated in cancer?, 23
   - Viruses and the beginnings of cancer biology, 25
   - Hens and teeth or bears and woods? The hens have it – cancer is rare, 25
   - The barriers to cancer, 25
   - What is the secret of cancer development… “timing”, 28
   - Location, location, location – the cancer environment: nanny or spartan state, 28
   - Cancer goes agricultural, 29
   - Cancer superhighways – blood vessels and lymphatics, 31
   - On your bike and turn the lights off before you go, 31
   - Catching cancer, 31
   - Hammering the hallmarks, 32
   - Painting a portrait of cancer, 33
   - The drugs don’t work, 34
   - Mechanism of origin rather than cell of origin – towards a new functional taxonomy of cancer, 35
   - Is it worth it?, 36
   - Conclusions and future directions, 36
   - Bibliography, 37
   - Appendix 1.1 History of cancer, 40

2 The Burden of Cancer, 43
   *William P. Steward and Anne L. Thomas*
   - Introduction, 43
   - Lung cancer, 45
   - Breast cancer, 49
   - Colorectal cancer, 53
   - Carcinoma of the prostate, 56
   - Renal carcinoma, 57
   - Skin cancer, 58
   - Carcinoma of the cervix, 60
   - Hematological malignancies, 60
   - Conclusions and future directions, 63
   - Outstanding questions, 63
   - Bibliography, 64
   - Questions for student review, 66

3 Nature and Nurture in Oncogenesis, 67
   *Michael Khan and Stella Pelengaris*
   - Introduction, 69
   - Risk factors, 73
   - Preventing cancers, 76
   - Cancer genetics – in depth, 78
   - Cancer genomics, 87
   - Gene–environment interactions, 89
   - Mutations and treatment, 89
   - Chemoprevention of cancer, 90
   - Risk factors act in combination, 90
   - Environmental causes of cancer, 93
   - The clinical staging and histological examination of cancer, 101
   - Screening and biomarkers, 102
   - Somatic gene mutations, epigenetic alterations and multistage tumorigenesis, 105
   - Conclusions and future directions, 107
   - Outstanding questions, 107
   - Bibliography, 107
   - Questions for student review, 109

4 DNA Replication and the Cell Cycle, 111
   *Stella Pelengaris and Michael Khan*
   - Introduction, 112
   - The cell cycle – overview, 114
   - Phases of the cell cycle, 120
   - The cell-cycle engine: cyclins and kinases, 123
   - Regulation by degradation, 126
   - Regulation by transcription, 129
   - MicroRNAs and the cell cycle, 131
   - Chromatin, 131
   - DNA replication and mitosis, 131
   - Checkpoints – putting breaks on the cell-cycle engine, 135
   - The DNA damage response (DDR), 136
10 Genetic Instability, Chromosomes, and Repair, 314
   Michael Khan

   Introduction, 316
   Telomere attrition and genomic instability, 321
   Sensing DNA damage, 323
   Repairing DNA damage, 325
   Checkpoints, 336
   Microsatellites and minisatellites, 343
   Chaperones and genomic instability, 344
   Cancer susceptibility syndromes involving genetic instability, 345
   Genomic instability and colon cancer, 346
   Conclusions and future directions, 346
   Outstanding questions, 347
   Bibliography, 347
   Questions for student review, 349

11 There Is More to Cancer than Genetics: Regulation of Gene and Protein Expression by Epigenetic Factors, Small Regulatory RNAs, and Protein Stability, 350
   Stella Pelengaris and Michael Khan

   Introduction, 351
   The language of epigenetics, 353
   Epigenetics, 353
   Methylation of DNA, 359
   Acetylation of histones and other posttranslational modifications, 360
   Epigenetics and cancer, 362
   CIMP and MIN and the “mutator phenotype”, 365
   Imprinting and loss of imprinting, 366
   Clinical use of epigenetics, 367
   Regulation of translation, 368
   Noncoding RNA and RNA interference, 369
   Therapeutic and research potential of RNAi, 371
   Treatments based on miRNA, 373
   Regulating the proteins, 373
   Therapeutic inhibition of the proteasome, 376
   Receptor degradation, 377
   Wrestling with protein transit – the role of SUMO and the promyelocytic leukemia (PML) body, 377
   Conclusions and future directions, 380
   Outstanding questions, 380
   Bibliography, 381
   Questions for student review, 382

12 Cell Adhesion in Cancer, 383
   Charles H. Streuli

   Introduction, 383
   Adhesive interactions with the extracellular matrix, 384
   Cell–cell interactions, 393
   Critical steps in the dissemination of metastases, 395
   E-cadherin downregulation in cancer leads to migration, 399
   Epithelial–mesenchymal transitions, 401
   Integrins, metalloproteinases, and cell invasion, 402
   Survival in an inappropriate environment, 404
   Conclusions, 406
   Outstanding questions, 406
   Bibliography, 407
   Questions for student review, 409

13 Tumor Immunity and Immunotherapy, 410
   Cassian Yee

   Introduction, 410
   Endogenous immune response, 411
   Effector cells in tumor immunity, 413
   Tumor antigens, 417
   Antigen-specific therapy of cancer, 420
   Clinical trials in vaccine therapy, 422
   Cytokine therapy of cancer, 423
   Tumor immune evasion, 424
   Clinical trials in immunomodulatory therapy, 425
   Conclusions, 425
   Bibliography, 426
   Questions for student review, 427

14 Tumor Angiogenesis, 429
   Christiana Ruhrberg

   Introduction, 429
   General principles of new vessel growth, 430
   Pathological neovascularization: tumor vessels, 430
   Basic concepts in tumor angiogenesis: the angiogenic switch, 432
   Vascular growth and differentiation factors: stimulators of the angiogenic switch, 432
   Role of inhibitors in angiogenesis, 436
   Clinical outcomes and future directions, 436
   Acknowledgments, 437
   Bibliography, 437
   Questions for student review, 437

15 Cancer Chemistry: Designing New Drugs for Cancer Treatment, 438
   Ana M. Pizarro and Peter J. Sadler

   Introduction, 439
   Historical perspective, 439
   The drug discovery process and preclinical development of a drug, 442
   Questions remaining, 457
   Conclusions and future directions, 457
   Bibliography, 458
   Questions for student review, 459

16 Biologically Targeted Agents from Bench to Bedside, 461
   Michael Khan, Peter Sadler, Ana M. Pizarro, and Stella Pelengaris

   Introduction, 463
   Targeted therapies, 465
   Cancer cell heterogeneity, 466
   Finding the molecular targets, 468
   Tumor regression in mice by inactivating single oncogenes, 468
   Targeted cancer therapies, 473
   Targeting oncogenes to treat cancer?, 473
   Questions for student review, 475
The concept of synthetic lethality and collateral vulnerability, 475
Clinical progress in biological and molecular targeted therapies, 476
Molecular targeted drugs – an inventory, 479
DNA damage responses, 490
Transcription factors, 491
Targeting epigenetic regulation of gene expression, 492
Hitting the extrinsic support network and preventing spread, 493
Gene therapy, antisense, and siRNA, 495
Resistance to targeted therapies – intrinsic resistance and emergence of secondary pathways and tumor escape, 497
Negative feedback loops and failure of targeted therapies, 500
Biomarkers to identify optimal treatments and tailored therapies, 501
Pharmacogenetics and pharmacogenomics, 505
Clinical trials in cancer, 506
Conclusions and future directions, 506
Bibliography, 507
Questions for student review, 508

17 The Diagnosis of Cancer, 509
Anne L. Thomas, Bruno Morgan, and William P. Steward
Introduction, 509
Clinical manifestations, 510
Investigations in oncological practice, 511
Non-invasive imaging techniques, 516
Future novel uses of imaging, 521
Proteomics and microarrays, 523
Circulating tumor cells, 523
Disease staging, 523
Conclusions and future directions, 524
Bibliography, 524
Questions for student review, 525

18 Treatment of Cancer: Chemotherapy and Radiotherapy, 526
Anne L. Thomas, J.P. Sage, and William P. Steward
Introduction, 526
Radiotherapy physics, 526
Radiobiology, 527
Treatment planning, 528
Recent advances, 529
Chemoradiation, 530
Conclusion, 540
Bibliography, 542
Questions for student review, 543

19 Caring for the Cancer Patient, 544
Nicky Rudd and Esther Waterhouse
Introduction, 544
Key concepts, 544
Communication with the cancer patient, 544
When is palliative care appropriate for cancer patients?, 545
Palliative care assessment, 545
Symptom control, 545
Respiratory symptoms, 547
Nausea and vomiting, 547
Bowel obstruction, 548
Constipation, 549
Fatigue, 549
Cachexia and anorexia, 549
Psychological problems, 549
The dying patient, 550
Supportive care, 550
An example of the care of a cancer patient, 551
Questions remaining, 551
Conclusions and future directions, 551
Bibliography, 552
Questions for student review, 553

20 Systems Biology of Cancer, 554
Walter Schubert, Norbert C.J. de Wit, and Peter Walden
Introduction, 556
Information flow in cells, 556
Model organisms and cancer models, 557
Array-based technologies: genomics, epigenomics, and transcriptomics, 559
SNPs, the HapMap, and the identification of cancer genes, 559
Cancer mRNA expression analysis, 562
CGH arrays, CpG island microarrays, and ChIP-on-Chip, 564
Next-generation sequencing, 564
Proteomics, 566
Posttranslational modifications, 567
Protein complexes and cellular networks, 569
Clinical applications of proteomics, 570
Toponomics: investigating the protein network code of cells and tissues, 571
Processing the images from the cyclical imaging procedures, 571
Structure, code, and semantics of the toponome: a high-dimensional combinatorial problem, 573
Detecting a cell surface protein network code: lessons from a tumor cell, 575
The molecular face of cells in diseases, 576
Individualized medicine and tailored therapies, 576
Discussion and conclusion, 579
Bibliography, 579
Internet resources, 581
Questions for student review, 582
Appendix 20.1 Techniques for the generation of genetically altered mouse models of cancer, 582

Glossary, 585
Answers to Questions, 597
Index, 603